1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Immunomodulator
        1.2.3 Proteasome Inhibitors
        1.2.4 Histone Deacetylase Inhibitors (HDACI)
        1.2.5 Monoclonal Antibody
        1.2.6 Other
    1.3 Market by Application
        1.3.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Drug Center
        1.3.4 Clinic
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Targeted Drugs for Multiple Myeloma Market Perspective (2017-2028)
    2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Region
        2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Size by Region (2017-2022)
        2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2023-2028)
    2.3 Targeted Drugs for Multiple Myeloma Market Dynamics
        2.3.1 Targeted Drugs for Multiple Myeloma Industry Trends
        2.3.2 Targeted Drugs for Multiple Myeloma Market Drivers
        2.3.3 Targeted Drugs for Multiple Myeloma Market Challenges
        2.3.4 Targeted Drugs for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue
        3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2017-2022)
        3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2017-2022)
    3.2 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
    3.4 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
        3.4.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2021
    3.5 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
    3.6 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
    3.7 Date of Enter into Targeted Drugs for Multiple Myeloma Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Multiple Myeloma Breakdown Data by Type
    4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2017-2022)
    4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2023-2028)
5 Targeted Drugs for Multiple Myeloma Breakdown Data by Application
    5.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Application (2017-2022)
    5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2017-2028)
    6.2 North America Targeted Drugs for Multiple Myeloma Market Size by Type
        6.2.1 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022)
        6.2.2 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028)
        6.2.3 North America Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Application
        6.3.1 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022)
        6.3.2 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028)
        6.3.3 North America Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Country
        6.4.1 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022)
        6.4.2 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2017-2028)
    7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type
        7.2.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022)
        7.2.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028)
        7.2.3 Europe Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application
        7.3.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022)
        7.3.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028)
        7.3.3 Europe Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Country
        7.4.1 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022)
        7.4.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (2017-2028)
    8.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Type
        8.2.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    8.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Application
        8.3.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    8.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region
        8.4.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Targeted Drugs for Multiple Myeloma Market Size (2017-2028)
    9.2 Latin America Targeted Drugs for Multiple Myeloma Market Size by Type
        9.2.1 Latin America Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022)
        9.2.2 Latin America Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028)
        9.2.3 Latin America Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    9.3 Latin America Targeted Drugs for Multiple Myeloma Market Size by Application
        9.3.1 Latin America Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022)
        9.3.2 Latin America Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028)
        9.3.3 Latin America Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    9.4 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country
        9.4.1 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022)
        9.4.2 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (2017-2028)
    10.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type
        10.2.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Share by Type (2017-2028)
    10.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application
        10.3.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Share by Application (2017-2028)
    10.4 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country
        10.4.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Celgene
        11.1.1 Celgene Company Details
        11.1.2 Celgene Business Overview
        11.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
        11.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.1.5 Celgene Recent Developments
    11.2 Exova
        11.2.1 Exova Company Details
        11.2.2 Exova Business Overview
        11.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
        11.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.2.5 Exova Recent Developments
    11.3 Natco Pharma
        11.3.1 Natco Pharma Company Details
        11.3.2 Natco Pharma Business Overview
        11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
        11.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.3.5 Natco Pharma Recent Developments
    11.4 Intas Pharmaceuticals
        11.4.1 Intas Pharmaceuticals Company Details
        11.4.2 Intas Pharmaceuticals Business Overview
        11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
        11.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.4.5 Intas Pharmaceuticals Recent Developments
    11.5 Indiabulls Pharmaceutical
        11.5.1 Indiabulls Pharmaceutical Company Details
        11.5.2 Indiabulls Pharmaceutical Business Overview
        11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
        11.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.5.5 Indiabulls Pharmaceutical Recent Developments
    11.6 Cipla
        11.6.1 Cipla Company Details
        11.6.2 Cipla Business Overview
        11.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
        11.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.6.5 Cipla Recent Developments
    11.7 Glenmark Pharmaceuticals
        11.7.1 Glenmark Pharmaceuticals Company Details
        11.7.2 Glenmark Pharmaceuticals Business Overview
        11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
        11.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.7.5 Glenmark Pharmaceuticals Recent Developments
    11.8 Dr Reddy's Laboratories
        11.8.1 Dr Reddy's Laboratories Company Details
        11.8.2 Dr Reddy's Laboratories Business Overview
        11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
        11.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.8.5 Dr Reddy's Laboratories Recent Developments
    11.9 Qilu Pharmaceutical
        11.9.1 Qilu Pharmaceutical Company Details
        11.9.2 Qilu Pharmaceutical Business Overview
        11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
        11.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.9.5 Qilu Pharmaceutical Recent Developments
    11.10 Chia Tai-Tianqing
        11.10.1 Chia Tai-Tianqing Company Details
        11.10.2 Chia Tai-Tianqing Business Overview
        11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
        11.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.10.5 Chia Tai-Tianqing Recent Developments
    11.11 Hanson Pharm
        11.11.1 Hanson Pharm Company Details
        11.11.2 Hanson Pharm Business Overview
        11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
        11.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.11.5 Hanson Pharm Recent Developments
    11.12 Meidakang Huakang Pharmaceutical
        11.12.1 Meidakang Huakang Pharmaceutical Company Details
        11.12.2 Meidakang Huakang Pharmaceutical Business Overview
        11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
        11.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.12.5 Meidakang Huakang Pharmaceutical Recent Developments
    11.13 Shandong Kongfu Pharmaceutical
        11.13.1 Shandong Kongfu Pharmaceutical Company Details
        11.13.2 Shandong Kongfu Pharmaceutical Business Overview
        11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
        11.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.13.5 Shandong Kongfu Pharmaceutical Recent Developments
    11.14 J&J
        11.14.1 J&J Company Details
        11.14.2 J&J Business Overview
        11.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
        11.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.14.5 J&J Recent Developments
    11.15 Takeda
        11.15.1 Takeda Company Details
        11.15.2 Takeda Business Overview
        11.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
        11.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.15.5 Takeda Recent Developments
    11.16 Amgen
        11.16.1 Amgen Company Details
        11.16.2 Amgen Business Overview
        11.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
        11.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.16.5 Amgen Recent Developments
    11.17 Bristol Myers Squibb
        11.17.1 Bristol Myers Squibb Company Details
        11.17.2 Bristol Myers Squibb Business Overview
        11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
        11.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.17.5 Bristol Myers Squibb Recent Developments
    11.18 Abbvie
        11.18.1 Abbvie Company Details
        11.18.2 Abbvie Business Overview
        11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
        11.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.18.5 Abbvie Recent Developments
    11.19 Seattle Genetics
        11.19.1 Seattle Genetics Company Details
        11.19.2 Seattle Genetics Business Overview
        11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
        11.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.19.5 Seattle Genetics Recent Developments
    11.20 Karyopharm Therapeutics
        11.20.1 Karyopharm Therapeutics Company Details
        11.20.2 Karyopharm Therapeutics Business Overview
        11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
        11.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.20.5 Karyopharm Therapeutics Recent Developments
    11.21 PDL BioPharma
        11.21.1 PDL BioPharma Company Details
        11.21.2 PDL BioPharma Business Overview
        11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
        11.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.21.5 PDL BioPharma Recent Developments
    11.22 Roche
        11.22.1 Roche Company Details
        11.22.2 Roche Business Overview
        11.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
        11.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.22.5 Roche Recent Developments
    11.23 Sumitomo
        11.23.1 Sumitomo Company Details
        11.23.2 Sumitomo Business Overview
        11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
        11.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.23.5 Sumitomo Recent Developments
    11.24 Merck
        11.24.1 Merck Company Details
        11.24.2 Merck Business Overview
        11.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
        11.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.24.5 Merck Recent Developments
    11.25 Biogen
        11.25.1 Biogen Company Details
        11.25.2 Biogen Business Overview
        11.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
        11.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.25.5 Biogen Recent Developments
    11.26 Schering-Plough
        11.26.1 Schering-Plough Company Details
        11.26.2 Schering-Plough Business Overview
        11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
        11.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.26.5 Schering-Plough Recent Developments
    11.27 Glaxo
        11.27.1 Glaxo Company Details
        11.27.2 Glaxo Business Overview
        11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
        11.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.27.5 Glaxo Recent Developments
    11.28 Chiron
        11.28.1 Chiron Company Details
        11.28.2 Chiron Business Overview
        11.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
        11.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022)
        11.28.5 Chiron Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Immunomodulator
    Table 3. Key Players of Proteasome Inhibitors
    Table 4. Key Players of Histone Deacetylase Inhibitors (HDACI)
    Table 5. Key Players of Monoclonal Antibody
    Table 6. Key Players of Other
    Table 7. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2017-2022)
    Table 11. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2023-2028)
    Table 13. Targeted Drugs for Multiple Myeloma Market Trends
    Table 14. Targeted Drugs for Multiple Myeloma Market Drivers
    Table 15. Targeted Drugs for Multiple Myeloma Market Challenges
    Table 16. Targeted Drugs for Multiple Myeloma Market Restraints
    Table 17. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Targeted Drugs for Multiple Myeloma Revenue Share by Players (2017-2022)
    Table 19. Global Top Targeted Drugs for Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2021)
    Table 20. Ranking of Global Top Targeted Drugs for Multiple Myeloma Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Targeted Drugs for Multiple Myeloma Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
    Table 24. Date of Enter into Targeted Drugs for Multiple Myeloma Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2017-2022)
    Table 28. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2023-2028)
    Table 30. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Targeted Drugs for Multiple Myeloma Revenue Share by Application (2017-2022)
    Table 32. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Targeted Drugs for Multiple Myeloma Revenue Share by Application (2023-2028)
    Table 34. North America Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Celgene Company Details
    Table 65. Celgene Business Overview
    Table 66. Celgene Targeted Drugs for Multiple Myeloma Product
    Table 67. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 68. Celgene Recent Developments
    Table 69. Exova Company Details
    Table 70. Exova Business Overview
    Table 71. Exova Targeted Drugs for Multiple Myeloma Product
    Table 72. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 73. Exova Recent Developments
    Table 74. Natco Pharma Company Details
    Table 75. Natco Pharma Business Overview
    Table 76. Natco Pharma Targeted Drugs for Multiple Myeloma Product
    Table 77. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 78. Natco Pharma Recent Developments
    Table 79. Intas Pharmaceuticals Company Details
    Table 80. Intas Pharmaceuticals Business Overview
    Table 81. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
    Table 82. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 83. Intas Pharmaceuticals Recent Developments
    Table 84. Indiabulls Pharmaceutical Company Details
    Table 85. Indiabulls Pharmaceutical Business Overview
    Table 86. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 87. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 88. Indiabulls Pharmaceutical Recent Developments
    Table 89. Cipla Company Details
    Table 90. Cipla Business Overview
    Table 91. Cipla Targeted Drugs for Multiple Myeloma Product
    Table 92. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 93. Cipla Recent Developments
    Table 94. Glenmark Pharmaceuticals Company Details
    Table 95. Glenmark Pharmaceuticals Business Overview
    Table 96. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
    Table 97. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 98. Glenmark Pharmaceuticals Recent Developments
    Table 99. Dr Reddy's Laboratories Company Details
    Table 100. Dr Reddy's Laboratories Business Overview
    Table 101. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product
    Table 102. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 103. Dr Reddy's Laboratories Recent Developments
    Table 104. Qilu Pharmaceutical Company Details
    Table 105. Qilu Pharmaceutical Business Overview
    Table 106. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 107. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 108. Qilu Pharmaceutical Recent Developments
    Table 109. Chia Tai-Tianqing Company Details
    Table 110. Chia Tai-Tianqing Business Overview
    Table 111. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product
    Table 112. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 113. Chia Tai-Tianqing Recent Developments
    Table 114. Hanson Pharm Company Details
    Table 115. Hanson Pharm Business Overview
    Table 116. Hanson Pharm Targeted Drugs for Multiple Myeloma Product
    Table 117. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 118. Hanson Pharm Recent Developments
    Table 119. Meidakang Huakang Pharmaceutical Company Details
    Table 120. Meidakang Huakang Pharmaceutical Business Overview
    Table 121. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 122. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 123. Meidakang Huakang Pharmaceutical Recent Developments
    Table 124. Shandong Kongfu Pharmaceutical Company Details
    Table 125. Shandong Kongfu Pharmaceutical Business Overview
    Table 126. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
    Table 127. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 128. Shandong Kongfu Pharmaceutical Recent Developments
    Table 129. J&J Company Details
    Table 130. J&J Business Overview
    Table 131. J&J Targeted Drugs for Multiple Myeloma Product
    Table 132. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 133. J&J Recent Developments
    Table 134. Takeda Company Details
    Table 135. Takeda Business Overview
    Table 136. Takeda Targeted Drugs for Multiple Myeloma Product
    Table 137. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 138. Takeda Recent Developments
    Table 139. Amgen Company Details
    Table 140. Amgen Business Overview
    Table 141. Amgen Targeted Drugs for Multiple Myeloma Product
    Table 142. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 143. Amgen Recent Developments
    Table 144. Bristol Myers Squibb Company Details
    Table 145. Bristol Myers Squibb Business Overview
    Table 146. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product
    Table 147. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 148. Bristol Myers Squibb Recent Developments
    Table 149. Abbvie Company Details
    Table 150. Abbvie Business Overview
    Table 151. Abbvie Targeted Drugs for Multiple Myeloma Product
    Table 152. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 153. Abbvie Recent Developments
    Table 154. Seattle Genetics Company Details
    Table 155. Seattle Genetics Business Overview
    Table 156. Seattle Genetics Targeted Drugs for Multiple Myeloma Product
    Table 157. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 158. Seattle Genetics Recent Developments
    Table 159. Karyopharm Therapeutics Company Details
    Table 160. Karyopharm Therapeutics Business Overview
    Table 161. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product
    Table 162. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 163. Karyopharm Therapeutics Recent Developments
    Table 164. PDL BioPharma Company Details
    Table 165. PDL BioPharma Business Overview
    Table 166. PDL BioPharma Targeted Drugs for Multiple Myeloma Product
    Table 167. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 168. PDL BioPharma Recent Developments
    Table 169. Roche Company Details
    Table 170. Roche Business Overview
    Table 171. Roche Targeted Drugs for Multiple Myeloma Product
    Table 172. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 173. Roche Recent Developments
    Table 174. Sumitomo Company Details
    Table 175. Sumitomo Business Overview
    Table 176. Sumitomo Targeted Drugs for Multiple Myeloma Product
    Table 177. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 178. Sumitomo Recent Developments
    Table 179. Merck Company Details
    Table 180. Merck Business Overview
    Table 181. Merck Targeted Drugs for Multiple Myeloma Product
    Table 182. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 183. Merck Recent Developments
    Table 184. Biogen Company Details
    Table 185. Biogen Business Overview
    Table 186. Biogen Targeted Drugs for Multiple Myeloma Product
    Table 187. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 188. Biogen Recent Developments
    Table 189. Schering-Plough Company Details
    Table 190. Schering-Plough Business Overview
    Table 191. Schering-Plough Targeted Drugs for Multiple Myeloma Product
    Table 192. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 193. Schering-Plough Recent Developments
    Table 194. Glaxo Company Details
    Table 195. Glaxo Business Overview
    Table 196. Glaxo Targeted Drugs for Multiple Myeloma Product
    Table 197. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 198. Glaxo Recent Developments
    Table 199. Chiron Company Details
    Table 200. Chiron Business Overview
    Table 201. Chiron Targeted Drugs for Multiple Myeloma Product
    Table 202. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2017-2022) & (US$ Million)
    Table 203. Chiron Recent Developments
    Table 204. Research Programs/Design for This Report
    Table 205. Key Data Information from Secondary Sources
    Table 206. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2021 VS 2028
    Figure 2. Immunomodulator Features
    Figure 3. Proteasome Inhibitors Features
    Figure 4. Histone Deacetylase Inhibitors (HDACI) Features
    Figure 5. Monoclonal Antibody Features
    Figure 6. Other Features
    Figure 7. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2021 VS 2028
    Figure 8. Hospital Case Studies
    Figure 9. Drug Center Case Studies
    Figure 10. Clinic Case Studies
    Figure 11. Other Case Studies
    Figure 12. Targeted Drugs for Multiple Myeloma Report Years Considered
    Figure 13. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 14. Global Targeted Drugs for Multiple Myeloma Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Targeted Drugs for Multiple Myeloma Market Share by Region: 2021 VS 2028
    Figure 16. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2021
    Figure 17. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2021
    Figure 19. North America Targeted Drugs for Multiple Myeloma Market Size YoY (2017-2028) & (US$ Million)
    Figure 20. North America Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2017-2028)
    Figure 21. North America Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2017-2028)
    Figure 22. North America Targeted Drugs for Multiple Myeloma Market Size Share by Country (2017-2028)
    Figure 23. United States Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Canada Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Europe Targeted Drugs for Multiple Myeloma Market Size YoY (2017-2028) & (US$ Million)
    Figure 26. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2017-2028)
    Figure 27. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2017-2028)
    Figure 28. Europe Targeted Drugs for Multiple Myeloma Market Size Share by Country (2017-2028)
    Figure 29. Germany Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. France Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. U.K. Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Italy Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Russia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Nordic Countries Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size YoY (2017-2028) & (US$ Million)
    Figure 36. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2017-2028)
    Figure 37. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2017-2028)
    Figure 38. Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Share by Region (2017-2028)
    Figure 39. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. South Korea Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Australia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 45. Latin America Targeted Drugs for Multiple Myeloma Market Size YoY (2017-2028) & (US$ Million)
    Figure 46. Latin America Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2017-2028)
    Figure 47. Latin America Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2017-2028)
    Figure 48. Latin America Targeted Drugs for Multiple Myeloma Market Size Share by Country (2017-2028)
    Figure 49. Mexico Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Brazil Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size YoY (2017-2028) & (US$ Million)
    Figure 52. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2017-2028)
    Figure 53. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2017-2028)
    Figure 54. Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size Share by Country (2017-2028)
    Figure 55. Turkey Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. UAE Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 59. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 60. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 61. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 62. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 63. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 64. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 65. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 66. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 67. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 68. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 69. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 70. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 71. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 72. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 73. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 74. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 75. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 76. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 77. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 78. PDL BioPharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 79. Roche Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 80. Sumitomo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 81. Merck Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 82. Biogen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 83. Schering-Plough Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 84. Glaxo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 85. Chiron Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2017-2022)
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed